vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $13.3M, roughly 1.0× Laird Superfood, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -13.2%, a 88.9% gap on every dollar of revenue.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
LSF vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $13.7M |
| Net Profit | $-1.8M | $10.4M |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | -86.5% |
| Net Margin | -13.2% | 75.7% |
| Revenue YoY | 15.0% | — |
| Net Profit YoY | -341.4% | 179.1% |
| EPS (diluted) | — | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | $13.7M | ||
| Q3 25 | $12.9M | $19.1M | ||
| Q2 25 | $12.0M | $8.1M | ||
| Q1 25 | $11.7M | $2.9M | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $11.8M | — | ||
| Q2 24 | $10.0M | — | ||
| Q1 24 | $9.9M | — |
| Q4 25 | $-1.8M | $10.4M | ||
| Q3 25 | $-975.1K | $-16.3M | ||
| Q2 25 | $-362.2K | $-15.8M | ||
| Q1 25 | $-156.2K | $-13.3M | ||
| Q4 24 | $-398.4K | — | ||
| Q3 24 | $-166.1K | — | ||
| Q2 24 | $-239.1K | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | -86.5% | ||
| Q3 25 | -7.7% | -10.1% | ||
| Q2 25 | -3.3% | -177.7% | ||
| Q1 25 | -1.9% | -472.7% | ||
| Q4 24 | -4.1% | — | ||
| Q3 24 | -2.3% | — | ||
| Q2 24 | -3.4% | — | ||
| Q1 24 | -11.0% | — |
| Q4 25 | -13.2% | 75.7% | ||
| Q3 25 | -7.6% | -85.4% | ||
| Q2 25 | -3.0% | -196.0% | ||
| Q1 25 | -1.3% | -452.7% | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | -1.4% | — | ||
| Q2 24 | -2.4% | — | ||
| Q1 24 | -10.3% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $35.3M |
| Total Assets | $19.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $137.5M | ||
| Q3 25 | $5.1M | $103.8M | ||
| Q2 25 | $3.9M | $121.6M | ||
| Q1 25 | $7.0M | $89.1M | ||
| Q4 24 | $8.3M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $7.6M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | $11.5M | $35.3M | ||
| Q3 25 | $12.8M | $-8.1M | ||
| Q2 25 | $13.4M | $7.1M | ||
| Q1 25 | $13.3M | $10.7M | ||
| Q4 24 | $13.2M | — | ||
| Q3 24 | $13.1M | — | ||
| Q2 24 | $12.6M | — | ||
| Q1 24 | $12.7M | — |
| Q4 25 | $19.2M | $154.7M | ||
| Q3 25 | $18.9M | $133.7M | ||
| Q2 25 | $20.4M | $133.8M | ||
| Q1 25 | $21.5M | $103.7M | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | $18.8M | — | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $17.6M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | $-2.0M | ||
| Q3 25 | $1.2M | $-17.5M | ||
| Q2 25 | $-2.8M | $-14.5M | ||
| Q1 25 | $-1.3M | $29.0M | ||
| Q4 24 | $339.2K | — | ||
| Q3 24 | $305.8K | — | ||
| Q2 24 | $642.7K | — | ||
| Q1 24 | $-422.3K | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
XLO
Segment breakdown not available.
